All In Biotech

Drug Trial Radar · NCT07150338

Outcome of Use of a Novel Modulator of Oxidative Phosphorylation on Kidney Function in Patients With Progressive Chronic Kidney Disease

Outcome of Use of a Novel Modulator of Oxidative Phosphorylation on Kidney Function in Patients With Chronic Kidney Disease

Last checked: Nov 19, 2026Latest source record: Sep 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

45

Actual

Start

May 20, 2021

Primary completion

Apr 20, 2022

Study completion Nov 20, 2022

Sponsor

Lead sponsor
Neukidney Inc.Industry
Sponsor type
Industry
First posted
Sep 2, 2025

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Outcome of use of a novel Modulator of Oxidative Phosphorylation on kidney function in patients with Chronic Kidney Disease

Conditions

  • Chronic Kidney Disease (Stage 3-4)
  • Chronic Kidney Disease (Stages 4 and 5)
  • Proteinuria

Interventions

  • QRX-3Drug

    Compounded new drug regime

  • EseronateDrug

    Neukidney innovative drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Decrease rate of GFR declineTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Premier Kidney clinic

    Pasadena, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.